Veracyte, Inc. has disclosed new ENZAMET trial data showing that its Decipher Prostate genomic test can identify which men with metastatic prostate cancer are more likely to benefit from adding docetaxel chemotherapy to androgen deprivation therapy and enzalutamide. The findings, presented at the 2026 American Society of Clinical Oncology Annual Meeting, position Decipher Prostate as a potential decision-support tool for triplet therapy in advanced prostate cancer.

Why does ENZAMET matter for chemotherapy selection in metastatic prostate cancer?

The ENZAMET analysis matters because metastatic hormone-sensitive prostate cancer has become a more crowded and more complicated treatment setting. Clinicians now have multiple ways to intensify therapy, including androgen receptor pathway inhibitors, chemotherapy, and triplet combinations. That progress has improved outcomes, but it has also created a practical problem: not every patient derives the same incremental benefit from chemotherapy, and not every patient can tolerate the added toxicity burden.

Decipher Prostate is being positioned as a way to turn that decision from a broad clinical judgment into a more biologically informed choice. The confirmed development is that the ENZAMET biomarker analysis used the genomic test in 634 patients and found a statistically significant treatment-by-biomarker interaction for adding docetaxel to androgen deprivation therapy plus enzalutamide. In plain clinical terms, the test appeared to separate patients whose disease biology made chemotherapy intensification more relevant from those who showed little benefit from the added treatment.

That is not a small distinction. Triplet therapy can be compelling when a patient has aggressive disease and enough physical reserve to tolerate it. However, docetaxel is not a casual add-on. It brings risks such as neutropenia, fatigue, neuropathy, infection vulnerability, and treatment disruption. A test that helps avoid unnecessary chemotherapy could therefore have clinical value even when it does not introduce a new drug, because better patient selection can change the risk-benefit equation of drugs already sitting on the shelf.

The limitation is that biomarker-driven treatment selection still has to survive the real world. ENZAMET provides strong evidence, but adoption depends on whether oncologists view the genomic score as sufficiently actionable alongside established clinical factors such as disease volume, performance status, comorbidities, patient preference, and access to oncology infrastructure. In metastatic prostate cancer, doctors rarely make decisions using a single variable. Decipher Prostate may sharpen the picture, but it will still need to fit into a busy, multi-factor treatment workflow.

How could Decipher Prostate shift the role of genomic testing beyond localized disease?

The larger significance is that Decipher Prostate is moving deeper into treatment selection rather than remaining only a prognostic tool. Genomic classifiers have already gained traction in localized prostate cancer, where they help refine recurrence risk and guide decisions around radiation, surveillance, or treatment intensification. The ENZAMET readout pushes that concept into advanced disease, where the stakes are different and the treatment choices are more consequential.

That shift matters commercially and clinically. In localized disease, genomic testing often helps determine how aggressive a treatment plan should be. In metastatic disease, the test could influence whether a patient receives chemotherapy as part of upfront triplet therapy. That is a more direct intervention point, and one that may be easier for clinicians and payers to understand if the evidence is reproduced and embedded into guidelines.

The comparison with earlier prostate cancer precision tools is also important. Much of precision oncology in prostate cancer has centred on DNA repair alterations, such as BRCA1, BRCA2, and other homologous recombination repair genes, particularly for targeted therapy selection in later-line settings. Decipher Prostate is different because it evaluates tumor biology through a transcriptomic risk profile rather than identifying a single druggable mutation. That broad biological readout may help explain treatment sensitivity in a way that mutation testing alone may not.

The unresolved question is whether clinicians will treat this as a true predictive test or as another risk stratification input. Predictive biomarkers are harder to establish than prognostic ones because they must show that the biomarker identifies differential treatment benefit, not merely worse baseline outcomes. The ENZAMET analysis appears designed to address that gap, but clinical confidence will depend on how clearly the test’s score threshold translates into everyday decision-making. If oncologists see too much ambiguity around cutoffs, patient subgroups, or disease volume categories, uptake may be slower than the data headline suggests.

What does this reveal about triplet therapy decision-making after ASCO 2026?

Triplet therapy has become one of the defining debates in metastatic hormone-sensitive prostate cancer. The logic is straightforward: attack the disease early with more intensive treatment before resistant clones dominate. The clinical challenge is equally straightforward: more treatment is not always better treatment for every patient.

The ENZAMET data appear to support a more selective model. Patients with higher Decipher scores and high-volume disease seemed to derive meaningful benefit from adding docetaxel, while patients with lower Decipher scores did not show the same chemotherapy benefit. This is important because disease volume has long influenced treatment intensity, but volume alone does not fully capture tumor biology. Two patients with high-volume disease may behave differently, and two patients with similar clinical staging may have different underlying genomic risk.

That is where Decipher Prostate could change the conversation. Instead of asking whether metastatic disease broadly justifies intensification, clinicians may increasingly ask whether the biology of the disease justifies chemotherapy specifically. This is a subtle but important shift. It does not weaken the role of clinical judgment. It gives that judgment another layer of evidence.

The risk is that real-world implementation could become uneven. Academic centers and high-volume oncology practices may be quicker to integrate genomic testing into metastatic treatment planning, especially when multidisciplinary teams are already comfortable with molecular tumor boards and risk classifiers. Community practices may need clearer workflow support, payer coverage, turnaround reliability, and guideline reinforcement before testing becomes routine. A genomic test can only influence a chemotherapy decision if the result arrives early enough to matter.

Why could this become commercially meaningful for Veracyte’s diagnostics business?

For Veracyte, the ENZAMET data strengthen the strategic profile of Decipher Prostate at a time when diagnostics companies are under pressure to prove that molecular tests change treatment decisions, not just risk estimates. The diagnostics-focused company already has a portfolio spanning prostate, bladder, thyroid, breast, and minimal residual disease testing. In prostate cancer, broader evidence across the disease continuum could make Decipher Prostate a more durable asset.

The commercial upside lies in clinical utility. Payers and health systems are more likely to support testing when it has a clear link to treatment selection, cost avoidance, or outcome improvement. If Decipher Prostate helps identify patients who can avoid chemotherapy without compromising expected benefit, the test may support both clinical and economic arguments. Avoided chemotherapy is not just about drug cost. It can also mean fewer infusion visits, fewer toxicity management episodes, and less patient disruption.

Investor sentiment around Veracyte will likely focus on whether this evidence translates into test volume growth, guideline positioning, and reimbursement momentum. Veracyte’s stock profile already reflects expectations for a diagnostics company with clinically differentiated assets rather than a commodity lab business. With the shares recently trading around $46.34 and the company valued near $3.77 billion, investors are likely to examine whether ASCO 2026 data can support a stronger growth story in urologic oncology.

The risk is that evidence generation and revenue conversion do not move at the same speed. Strong trial data can lift clinical credibility immediately, but reimbursement updates, physician education, ordering behavior, and guideline incorporation can take time. Diagnostics investors know this movie well. The first act is validation, the second act is adoption, and the third act is durable payment. The ENZAMET data help the first act. The next test is whether Veracyte can move the story through the other two without losing momentum.

How does the localized prostate cancer evidence broaden the Decipher Prostate story?

The ASCO 2026 update also included complementary evidence in high-risk localized prostate cancer, where Decipher Prostate was evaluated across mature NRG/RTOG trial datasets. That matters because it gives the test a more continuous role across the prostate cancer pathway, from localized treatment planning to metastatic chemotherapy selection. For clinicians, continuity can be powerful. A test that repeatedly proves useful at different decision points becomes easier to remember, easier to explain, and easier to institutionalize.

In localized disease, the key value proposition is risk refinement. Clinical classifications such as National Comprehensive Cancer Network risk groups are useful, but they can leave large gray zones. Genomic testing can help separate patients who may need escalation from those who might avoid overtreatment. If Decipher Prostate improves prognostic accuracy and reclassifies a meaningful share of high-risk patients, it could support more tailored use of radiation, systemic therapy, or intensified regimens.

The commercial context is also attractive because localized prostate cancer includes a much larger patient pool than de novo metastatic disease. A test with utility in both localized and metastatic settings may have broader ordering opportunities and stronger brand recognition among urologists, radiation oncologists, and medical oncologists. That multi-specialty relevance is valuable in prostate cancer, where patient management often crosses professional boundaries.

The limitation is that broader use can create a messaging challenge. Veracyte must make clear which clinical decision each evidence package supports. A test that is used for active surveillance, localized intensification, metastatic chemotherapy selection, and broader risk classification can become powerful, but it can also become confusing if the clinical use cases are not sharply defined. The opportunity is to build a continuum narrative. The risk is to sound like one test is being stretched across too many decisions without enough practical guidance at each point.

What should clinicians and industry observers watch next after the ENZAMET readout?

The most important next step is guideline relevance. In oncology, strong conference data can influence discussion, but practice change tends to accelerate when guideline panels, payer policies, and major cancer centers begin embedding the evidence into formal pathways. For Decipher Prostate, the question is whether the ENZAMET findings push genomic testing closer to routine consideration before chemotherapy intensification in metastatic hormone-sensitive prostate cancer.

Clinicians will also watch how well the test performs across patient subgroups. The announced findings highlight higher Decipher scores, high-volume disease, and the added value of docetaxel in a triplet approach. The real-world question is how the test should be used in patients with lower-volume disease, borderline performance status, older age, comorbidities, or competing treatment priorities. These are not edge cases. They are daily oncology clinic realities.

Regulatory and reimbursement dynamics are also worth watching, even if the test is not being discussed like a drug approval candidate. Diagnostics adoption often hinges on payer confidence in analytical validity, clinical validity, and clinical utility. ENZAMET supports clinical utility, but payers may still ask how often the test changes management, whether it reduces unnecessary treatment, and whether those changes improve outcomes or lower downstream costs.

For industry observers, the bigger signal is that cancer diagnostics companies are moving deeper into therapy optimization. The next competitive frontier is not only detecting cancer or estimating recurrence risk. It is helping clinicians decide which patient should receive which treatment, at which intensity, and at which point in the disease course. Veracyte’s Decipher Prostate data fit that direction neatly, but the company will need to prove that evidence can become behavior.

Could this make chemotherapy avoidance a stronger precision oncology endpoint?

The most interesting implication of the ENZAMET data is not only that some patients may benefit from chemotherapy. It is that others may be spared it. Precision oncology is often framed around adding new targeted drugs, but some of its most practical value may come from avoiding unnecessary treatment. In prostate cancer, where many patients live for years across multiple lines of therapy, preserving quality of life and avoiding avoidable toxicity can be clinically meaningful.

That said, chemotherapy avoidance is a delicate message. It must be grounded in evidence, not convenience. Clinicians will need confidence that lower Decipher scores truly identify patients unlikely to gain meaningful incremental benefit from docetaxel in the relevant treatment setting. Patients and physicians may also differ in risk tolerance. Some may prefer maximal upfront treatment despite uncertain incremental benefit, while others may strongly prioritize avoiding chemotherapy toxicity.

For Veracyte, this creates both an opportunity and a responsibility. The commercial appeal of a test that helps tailor chemotherapy is obvious. However, the credibility of that claim depends on careful education, precise clinical language, and avoidance of overstatement. The test should not be framed as replacing oncologist judgment. Its stronger positioning is as a biological decision-support tool that helps make intensification more rational.

The broader industry implication is clear. As metastatic prostate cancer treatment becomes more personalized, the winners will not only be drug developers. Diagnostics companies that can prove treatment-selection utility in randomized trial datasets may become more central to oncology workflows. ENZAMET gives Veracyte a stronger seat at that table. The hard part begins now: turning a compelling ASCO readout into routine, reimbursed, and trusted clinical practice.

  androgen deprivation therapy, ASCO 2026, Decipher Prostate, docetaxel, enzalutamide, ENZAMET, metastatic prostate cancer, prostate cancer, Veracyte